2 results
07/Mar/2023
DOI: 10.31744/einstein_journal/2023AO0089
Highlights Lymphoproliferative disorders were associated with lower vaccine response rates than other disorders. Previous exposure to COVID-19 before vaccination was associated with higher antibody values. The duration of anti-B-lymphocyte therapy related to vaccination had an effect on response rates. The incidence of adverse effects of patients with onco-hematological diseases was similar to that of the healthy population. ABSTRACT Objective To evaluate the influence of onco-hematological pathologies on seroconversion to COVID-19 vaccines, in addition to the effects of chemotherapy treatment […]
Keywords: Coronavirus infections; COVID-19; Immunogenicity; Lymphoproliferative disorders; Multiple myeloma; Myelodysplastic-myeloproliferative diseases; SARS-CoV-2; Seroconversion; Vaccines
31/Jan/2014
DOI: 10.1590/S1679-45082013000400025
Philadelphia-chromosome negative chronic myeloproliferative neoplasms are clonal hematologic diseases characterized by hematopoietic progenitor independence from or hypersensitivity to cytokines. The cellular and molecular mechanisms involved in the pathophysiology of myeloproliferative neoplasms have not yet been fully clarified. Pathophysiologic findings relevant for myeloproliferative neoplasms are associated with genetic alterations, such as, somatic mutation in the gene that codifies JAK-2 (JAK V617F). Deregulation of the process of programmed cellular death, called apoptosis, seems to participate in the pathogenesis of these disorders. It […]
Keywords: Apoptosis; Myelodysplastic-myeloproliferative diseases; Proto-oncogene proteins c-bcl-2; Receptors, death domain